病毒性与代谢功能障碍相关脂肪性肝病相关肝细胞癌肠道菌群不同但代谢组学特征共通,影响联合免疫治疗结局
研究前瞻性纳入2021年1月至2024年4月接受一线联合免疫治疗的77例病毒性肝细胞癌(V-HCC)和25例代谢功能障碍相关脂肪性肝病相关肝细胞癌(MASLD-HCC)患者,分析治疗前粪便菌群/代谢物及血清细胞因子/趋化因子与持久肿瘤缓解、总生存期(OS)和无进展生存期(PFS)的关联。结果显示两组肠道菌群组成不同,但粪便乙酸盐水平均为持久缓解、PFS和OS的共同显著预测因素,高乙酸盐患者OS和PFS显著更长。
要点
- MASLD-HCC与V-HCC肠道菌群组成不同,但粪便乙酸盐均为联合免疫治疗持久缓解、PFS和OS的共同显著预测因素。
- 粪便乙酸盐较高者OS中位25.2个月 vs 11.3个月(p<0.001),PFS中位15.3个月 vs 4.2个月(p<0.001)。
- MASLD-HCC持久缓解者富含Mediterraneibacter gnavus ATCC 29149且短链脂肪酸和熊去氧胆酸显著更高。
核心结论
- 不同的肠道菌群但共有的有益代谢物(尤其是粪便乙酸盐)与MASLD-HCC和V-HCC联合免疫治疗的持久缓解及生存改善相关。
- 粪便乙酸盐可能作为优化HCC治疗的潜在生物标志物和治疗靶点。
研究设计与样本
- 前瞻性研究,2021年1月至2024年4月纳入77例V-HCC患者和25例MASLD-HCC患者,均接受一线联合免疫治疗。
- 分析治疗前粪便菌群/代谢物及血清细胞因子/趋化因子与持久肿瘤缓解、OS和PFS的关联。
主要发现
- MASLD-HCC患者粪便以Bacteroides ovatus、Kluyvera georgiana、Klebsiella oxytoca和Enterococcus faecium为主,短链脂肪酸(SCFAs)和熊去氧胆酸(UDCA)水平低于V-HCC。
- MASLD-HCC持久缓解者富含Mediterraneibacter gnavus ATCC 29149,且SCFAs(乙酸盐、丙酸盐、丁酸盐和异丁酸盐)和UDCA显著更高。
- V-HCC持久缓解者以双歧杆菌属为主,SCFAs同样富集。
- 在MASLD-HCC和V-HCC中,粪便乙酸盐水平均为持久缓解、PFS和OS的共同显著预测因素。
- 乙酸盐较高者OS显著更长(中位25.2 vs 11.3个月;p<0.001),PFS显著更长(中位15.3 vs 4.2个月;p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Gut microbiota could modulate the outcome of cancer immunotherapy, including HCC. Although metabolic dysfunction-associated steatotic liver disease-related HCC (MASLD-HCC) and viral hepatitis-related HCC (V-HCC) exhibit different tumor microenvironments and gut microbiome composition, both respond to combination immunotherapy. This study aimed to investigate whether distinct microbiota/metabolomic signatures are associated with outcomes of combination immunotherapy in MASLD-HCC and V-HCC, separately. APPROACH AND RESULTS: Between January 2021 and April 2024, 77 V-HCC patients and 25 with MASLD-HCC initiating first-line combination immunotherapy were prospectively enrolled. Pre-treatment fecal microbiota/metabolites and serum cytokines/chemokines were analyzed in association with durable tumor response, overall survival (OS) and progression-free survival (PFS). MASLD-HCC patients showed predominant fecal Bacteroides ovatus , Kluyvera georgiana , Klebsiella oxytoca , and Enterococcus faecium , with lower levels of short-chain fatty acids (SCFAs) and ursodeoxycholic acid (UDCA) compared to V-HCC. Durable responders (DRs) of MASLD-HCC had enriched Mediterraneibacter gnavus ATCC 29149 and significantly higher SCFAs (acetate, propionate, butyrate, and isobutyrate) and UDCA. In contrast, V-HCC-DRs were characterized by predominant Bifidobacterium and similarly enriched SCFAs. In both MASLD-HCC and V-HCC, fecal acetate level was a common significant predictor of DR, PFS, and OS. Patients with higher acetate levels had significantly longer OS (median: 25.2 vs. 11.3 mo; p <0.001) and PFS (median: 15.3 vs. 4.2 mo; p <0.001). CONCLUSIONS: Distinct gut microbiota, but shared beneficial metabolites, particularly fecal acetate, are associated with durable response to combination immunotherapy and improved survival in both MASLD-HCC and V-HCC. Fecal acetate may serve as a potential biomarker and therapeutic target for optimizing HCC treatment.
引用
- Lee PC, Wu CJ, Hung YW, et al. Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy. Hepatology. 2025. PMID: 40587824. doi:10.1097/HEP.0000000000001446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。